This is the first year that the Panel has reviewed essential-use requests from Parties operating under paragraph 1 of Article 5 . The Panel noted that it found it difficult to assess these nominations adequately owing , in particular , to a shortage of data on the availability and affordability of alternatives to chlorofluorocarbon ( CFC ) -based metered-dose inhalers for both the metered-dose inhaler manufacturing/nominating Parties and especially for the Parties operating under paragraph 1 of Article 5 listed as the destinations for their products .